The Impact of Pharmacovigilance on Patient Safety: A Comprehensive Review

Pharmacovigilance (PV) plays a crucial role in ensuring the safety of medicines, but it faces several challenges as drug safety monitoring evolves. One key challenge is the increasing volume and complexity of data, especially with the rise of biologics, personalized medicines, and digital health technologies. Integrating big data, real-world evidence, and artificial intelligence (AI) for signal detection and risk assessment offers significant opportunities for enhancing PV practices. However, data privacy concerns, regulatory hurdles, and the need for standardized data formats remain obstacles. Another challenge is the underreporting of adverse drug reactions (ADRs), which limits the completeness of safety profiles. The expanding use of social media and patient-reported outcomes provides new opportunities to improve ADR reporting, but it also raises issues related to data validation and signal reliability. In the future, PV systems must adapt to emerging therapeutic areas, such as gene therapies and cell-based medicines, which present unique safety monitoring challenges. Regulatory agencies must refine global collaboration and harmonize pharmacovigilance standards to ensure effective monitoring across borders. Advancements in technology, better stakeholder engagement, and improved data integration hold promise to address these challenges and enhance drug safety monitoring worldwide.